Kamran Waidha

6PUBLICATIONS
17CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsProteins and peptides
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 13, 2026
Recognition of ErbB Family Dimers by the EGF-like Domain of NRG1alpha and Beta: Implications for Ligand-Based CAR Therapy.

|Feb 16, 2026
PKC-eta promotes breast cancer metastasis by regulating the Hippo-YAP signaling pathway.

Vijayasteltar B Liju, Kamran Waidha, Amitha Muraleedharan

|Jul 24, 2025
HLA-E[pHLA-G] complex-specific monoclonal antibody enhancing NK activity in multiple myeloma.

Muhammad Abu Ahmad, Olga Radinsky, Bar Kaufman

|May 13, 2023
In Vitro and In Vivo Therapeutic Potential of 6,6'-Dihydroxythiobinupharidine (DTBN) from Nuphar lutea on Cells and K18-hACE2 Mice Infected with SARS-CoV-2.

Shay Weiss, Kamran Waidha, Saravanakumar Rajendran

|Aug 27, 2021
Inhibition of Cysteine Proteases by 6,6'-Dihydroxythiobinupharidine (DTBN) from Nuphar lutea.

Kamran Waidha, Udi Zurgil, Efrat Ben-Zeev

|Jun 02, 2021
6,6'-Dihydroxythiobinupharidine (DTBN) Purified from Nuphar lutea Leaves Is an Inhibitor of Protein Kinase C Catalytic Activity.

Kamran Waidha, Nikhil Ponnoor Anto, Divya Ram Jayaram

Pageof 1

Frequent Collaborators

3 joint publications

Saravanakumar Rajendran

3 joint publications

Jacob Gopas

2 joint publications

Moshe Elkabets

1 joint publications

Nikhil Ponnoor Anto